DrugDashboards

JORNAY PM Extended-Release

Methylphenidate Hydrochloride · METHYLPHENIDATE HYDROCHLORIDE 80 mg/1 · Capsule · Oral · Ironshore Pharmaceuticals Inc.

NDC 71376-0204-03 · 100 CAPSULE in 1 BOTTLE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $15.40 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$15.40per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D point of sale (median)$14.86per unitnegotiated price across 2 plans — before rebates · Jul 1, 2024

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$14.86per unit
middle half $14.86$14.86 · 2 plans · Jul 1, 2024
Est. net of rebates
$8.92–$11.14
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.

NADAC price per unit

$0$10.00$20.00Apr 2020Sep 2026$15.40
33 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$462.03
#90 count
$1386.10

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$24.3M
57,169 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for methylphenidate hydrochloride (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA209311
TE code
Approval date
Aug 8, 2018
Patents / exclusivity
80 patents, 0 exclusivities
TypeNumber / codeExpires
patent9028868Mar 23, 2032
patent9034902Mar 23, 2032
patent8916588Mar 23, 2032
patent9603809Mar 23, 2032
patent9028868Mar 23, 2032
patent10292937Mar 23, 2032
patent10292937Mar 23, 2032
patent9603809Mar 23, 2032
patent8916588Mar 23, 2032
patent8916588Mar 23, 2032
patent8916588Mar 23, 2032
patent9603809Mar 23, 2032

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Methylphenidate Hydrochloride (Capsule)

LabelerStrengthFirst seenLast seen
Catalent Pharma Solutions, LLCMETHYLPHENIDATE HYDROCHLORIDE 40 mg/1Jul 15, 2026Sep 2, 2026
Catalent Pharma Solutions, LLCDEXMETHYLPHENIDATE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Ironshore Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 20 mg/1Jul 15, 2026Sep 2, 2026
Ironshore Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 80 mg/1Jul 15, 2026Sep 2, 2026
Ironshore Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 40 mg/1Jul 15, 2026Sep 2, 2026
Ironshore Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Ironshore Pharmaceuticals Inc.METHYLPHENIDATE HYDROCHLORIDE 100 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "JORNAY PM Extended-Release — NDC 71376-0204-03," retrieved September 3, 2026, https://drugdashboards.com/drug/71376020403.

Free to cite with attribution — see how the data is put together.